Neuland Laboratories Limited published an article examining why impurity profiling has become a strategic component of peptide development and how advanced analytical approaches are helping address these challenges.

Founded in 1984, Neuland Labs is a globally recognised Contract Development and Manufacturing Organization (CDMO), offering comprehensive customised NCE development services. Our team comprises highly skilled scientists, engineers, and technicians who utilise their expertise and advanced technologies to address the complex and evolving requirements of our clients. We collaborate with pharmaceutical and biotechnology companies to support all aspects of their chemistry needs, ranging from early development stages to commercial manufacturing, including process development, optimisation, analytical testing, and regulatory compliance. Neuland Labs possesses the capabilities and flexibility to manage both single-step processes and complete synthesis, handling projects from lab to commercial supply. We provide quantities suitable for clinical trials as well as full commercial-scale production of new chemical entities (NCEs), key starting materials (KSMs), active pharmaceutical ingredients (APIs), and their intermediates, ensuring efficient tech transfer timelines.

Founded 1984